Shanghai Pharmaceuticals Holding Co Ltd Class H (HK:2607)
:2607
Want to see HK:2607 full AI Analyst Report?
2607 Stock Chart & Stats
HK$11.91
-HK$0.08(-0.65%)
At close: 4:00 PM EST
HK$11.91
-HK$0.08(-0.65%)
Day’s Range― - ―
52-Week RangeHK$10.96 - HK$13.12
Previous CloseN/A
Volume2.05M
Average Volume (3M)2.90M
Market Cap
HK$63.06B
Enterprise ValueHK$92.52B
Total Cash (Recent Filing)HK$40.98B
Total Debt (Recent Filing)HK$62.41B
Price to Earnings (P/E)10.4
Beta0.71
Next Earnings
Aug 27, 2026EPS Estimate
0.5Next Dividend Ex-DateN/A
Dividend Yield2.67%
Share Statistics
EPS (TTM)1.55
Shares Outstanding919,072,700
10 Day Avg. Volume2,690,085
30 Day Avg. Volume2,904,360
Financial Highlights & Ratios
PEG Ratio0.26
Price to Book (P/B)0.50
Price to Sales (P/S)0.13
P/FCF Ratio9.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$13.50Price Target Upside13.35% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)1.41
Revenue Forecast (FY)HK$297.42B
Bulls Say, Bears Say
Bulls Say
Diversified Business ModelCombines large-scale distribution, manufacturing and related healthcare services to create multiple durable revenue streams. Distribution scale sustains volumes and customer relationships with hospitals and pharmacies, while manufacturing enables capture of higher-value product sales and vertical integration benefits over time.
Steady Revenue & EarningsConsistent top-line expansion and recurring positive earnings provide durable operational stability. Multi-year revenue growth (2021–2025) and improving net income reduce execution risk, supporting reinvestment in logistics, commercial reach and manufacturing scale that underpin medium-term competitiveness.
Positive Cash GenerationPersistent positive operating cash flow and a rebound in FCF enhance financial flexibility for capex, working-capital needs and shareholder returns. Reliable cash generation lowers dependence on external funding and supports steady investment in distribution infrastructure and manufacturing capabilities.
Bears Say
Thin Profit MarginsVery low net margins mean limited cushion against cost inflation, procurement pressure or reimbursement shifts. Margin structural thinness typical of distribution constrains retained earnings for growth, increases sensitivity to adverse mix shifts, and makes long-term profitability fragile without efficiency gains.
Moderate LeverageDebt at roughly two-thirds of equity indicates moderate leverage that can limit strategic flexibility. Interest obligations and refinancing risk may constrain ability to fund large-scale investments or M&A, and reduce the balance sheet buffer available during sector slowdowns or working-capital stress.
Working-capital IntensityModerate cash conversion and working-capital intensity point to potential volatility tied to receivables and inventory cycles. That dynamic can pressure liquidity during slower collections or inventory build, necessitating short-term financing and constraining margin recovery and reinvestment capacity over time.
Shanghai Pharmaceuticals Holding Co News
2607 FAQ
What was Shanghai Pharmaceuticals Holding Co Ltd Class H’s price range in the past 12 months?
Shanghai Pharmaceuticals Holding Co Ltd Class H lowest stock price was HK$10.96 and its highest was HK$13.12 in the past 12 months.
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s market cap is HK$63.06B.
When is Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s upcoming earnings report date is Aug 27, 2026 which is in 75 days.
How were Shanghai Pharmaceuticals Holding Co Ltd Class H’s earnings last quarter?
Shanghai Pharmaceuticals Holding Co Ltd Class H released its earnings results on Apr 29, 2026. The company reported HK$0.438 earnings per share for the quarter, beating the consensus estimate of HK$0.407 by HK$0.031.
Is Shanghai Pharmaceuticals Holding Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Pharmaceuticals Holding Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Pharmaceuticals Holding Co Ltd Class H pay dividends?
Shanghai Pharmaceuticals Holding Co Ltd Class H pays a Notavailable dividend of HK$0.132 which represents an annual dividend yield of 2.67%. See more information on Shanghai Pharmaceuticals Holding Co Ltd Class H dividends here
What is Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate?
Shanghai Pharmaceuticals Holding Co Ltd Class H’s EPS estimate is 0.5.
How many shares outstanding does Shanghai Pharmaceuticals Holding Co Ltd Class H have?
Shanghai Pharmaceuticals Holding Co Ltd Class H has 919,072,700 shares outstanding.
What happened to Shanghai Pharmaceuticals Holding Co Ltd Class H’s price movement after its last earnings report?
Shanghai Pharmaceuticals Holding Co Ltd Class H reported an EPS of HK$0.438 in its last earnings report, beating expectations of HK$0.407. Following the earnings report the stock price went up 0.862%.
Which hedge fund is a major shareholder of Shanghai Pharmaceuticals Holding Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2607
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Pharmaceuticals Holding Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
0.71%
12-Months-Change
Fundamentals
Return on Equity
7.64%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Shanghai Pharmaceuticals Holding Co Ltd Class H
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company based in Shanghai, People's Republic of China, maintains a robust presence across the pharmaceutical and healthcare industries. Its core activities involve the research, development, production, distribution, and retail of medical and wellness products. The company is strategically divided into Production, Distribution, Retail, and Other segments. Its comprehensive product portfolio includes Western and traditional Chinese medicines, health supplements, and medical devices, addressing a broad spectrum of therapeutic areas such as oncology, cardiovascular health, central nervous system disorders, general infections, immunology, digestive and metabolic conditions, and respiratory ailments, totaling approximately 700 distinct drug varieties. Beyond manufacturing, Shanghai Pharmaceuticals offers extensive pharmaceutical supply chain solutions, encompassing warehousing, logistics, and value-added services for manufacturers, hospitals, distributors, and retail pharmacies. The company also boasts a significant retail footprint, operating a network of approximately 2,000 retail pharmacies across 24 provinces, alongside an active online drug business. Furthermore, it provides various specialized services, including consulting, asset management, clinical trials, medical aid programs, physician and patient education, e-prescription management, and remote/cloud-based hospital services. Established in 1994, Shanghai Pharmaceuticals Holding Co., Ltd. operates as a subsidiary of Shanghai Pharmaceutical (Group) Co., Ltd.
2607 Stock 12 Month Forecast
Average Price Target
HK$13.50
▲(13.35% Upside)
Technical Analysis
China Health Group
―
Sinopharm Group Co
―
IVD Medical Holding Limited
―
Medlive Technology Co., Ltd.
―
Charmacy Pharmaceutical Co., Ltd. Class H
―
Options Prices
Currently, No data available
---